Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

10.9

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.62

Max

11.09

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+169.9% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-126M 999M
Ouverture précédente	10.9
Clôture précédente	10.9

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 oct. 2026, 23:55 UTC

Zoom Communications Inc is trading higher in after-market hours, showing a slight advance since Friday's close amid routine fluctuations within its one-month trading range.

2 oct. 2026, 23:55 UTC

Campbell's Co saw a modest increase in after-market trading on Friday, recovering from earlier losses and moving into positive territory.

2 oct. 2026, 23:55 UTC

HCA Healthcare Inc is advancing in after-market trading, remaining near the upper end of its one-month range despite earlier session pullbacks.

2 oct. 2026, 23:55 UTC

Zillow Group Inc is trading modestly higher in after-market hours, having pulled back from an earlier peak following Friday's close.

2 oct. 2026, 23:55 UTC

Dave and Buster's Entertainment, Inc. is seeing a notable decline in after-market trading, continuing lower since Friday's close amid broader weakness.

2 oct. 2026, 23:55 UTC

Ironwood Pharmaceuticals Inc's shares traded roughly flat in after-market hours, following recent lower closes amid broader market trends in labor force engagement and wage growth.

2 oct. 2026, 23:51 UTC

8x8 Inc saw a sharp decline during after-market hours, continuing significant losses since Friday's close and nearing the low end of its after-market range.

2 oct. 2026, 23:51 UTC

monday.com Ltd is trading modestly higher in after-market hours, recovering from a low point after the regular session and settling near its one-month trading range.

2 oct. 2026, 23:51 UTC

DoorDash Inc. is trading modestly lower in after-market hours, retracing from an earlier gain, with no significant catalysts driving the move.

2 oct. 2026, 23:51 UTC

ATI Inc declined in after-market trading, moving lower since Friday's close, with unusual price movement near the lower end of its one-month range.

2 oct. 2026, 23:51 UTC

Titan Machinery Inc is trading lower in after-market hours, having retraced sharply from a slight gain earlier in the session.

2 oct. 2026, 23:51 UTC

Goodyear Tire & Rubber Co is trading modestly higher in after-market hours, despite pulling back earlier in the session from a session high.

2 oct. 2026, 23:51 UTC

Social Media

Mattel Inc is declining in after-market trading following Roger Lynch's appointment as CEO, succeeding Ynon Kreiz amid ongoing challenges and flat revenue growth.

2 oct. 2026, 23:51 UTC

Brazil's Inflation Rate Release on October 9, 2026, Sparks Investor Caution Amid Global Commodity Price Surge.

2 oct. 2026, 23:51 UTC

Brazil's Inflation Rate Expected to Show Pressure Amid Global Price Increases Ahead of October 9 Release

2 oct. 2026, 23:51 UTC

In after-market trading, Blue Owl Capital Corp has advanced notably since Friday's close, despite a slight retracement from a high point above the previous close.

2 oct. 2026, 23:51 UTC

OneMain Holdings Inc is trading higher in after-market hours, continuing a positive trend after three consecutive sessions of gains.

2 oct. 2026, 23:50 UTC

Wendy's Co is trading higher in after-market hours, reflecting a notable increase from Friday's close, despite four consecutive sessions finishing lower.

2 oct. 2026, 23:46 UTC

Correlated Moves

DHT Holdings Inc traded modestly lower in after-market hours amid weaker job growth concerns, while Frontline PLC also declined despite earlier gains.

2 oct. 2026, 23:45 UTC

Mosaic Co's shares advanced in after-market trading, recovering from three consecutive declines and settling higher since Friday's close.

2 oct. 2026, 23:45 UTC

Royal Caribbean Cruises Ltd saw a slight decline during after-market hours, trading roughly flat compared to Friday's close after recent upward momentum.

2 oct. 2026, 23:45 UTC

Viatris Inc declined in after-market hours, continuing a trend of lower prices observed over the past four sessions since Friday's close.

2 oct. 2026, 23:45 UTC

Rockwell Automation Inc is trading modestly higher in after-market hours, rebounding sharply to finish near its session high after notable volatility.

2 oct. 2026, 23:45 UTC

In after-market trading, Molson Coors Beverage Co is declining, remaining near the lower end of its one-month range since Friday's close.

2 oct. 2026, 23:42 UTC

Ellington Financial Inc is rising in after-market trading, recovering from a trend of five consecutive lower sessions since Friday's close.

2 oct. 2026, 23:41 UTC

Energy Fuels Inc rose sharply in after-market trading, advancing since Friday's close despite being near the lower end of its one-month trading range.

2 oct. 2026, 23:41 UTC

OPKO Health Inc is trading lower in after-market hours, continuing a trend of declines following a sharp drop from its peak shortly after the market closed.

2 oct. 2026, 23:41 UTC

Correlated Moves

Onto Innovation Inc is trading higher in after-market hours, reflecting upward movement amid a broader trend in the semiconductor sector.

2 oct. 2026, 23:41 UTC

Correlated Moves

NRG Energy Inc is advancing in after-market trading, potentially driven by Vistra Corp's rise following the U.S. Department of Energy's $4 billion loan extension for nuclear upgrades.

2 oct. 2026, 23:40 UTC

Dole PLC declined significantly during after-market hours on Friday, reaching a low point near the lower end of its one-month trading range.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

169.9% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 169.9%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.